KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe Chronic Kidney Disease (CKD) patients with and without hemodialysis

The pharmacology experimental platform allows KBP to identify and progress those
products with significant differentiation.